Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 13/20 | 0.92 |
| ▸ | PGR | P06401 | 4/20 | 0.92 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.92 |
| ▸ | USP2 | O75604 | 3/20 | 0.92 |
| ▸ | MEN1 | O00255 | 1/20 | 0.92 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.92 |
| ▸ | MMP1 | P03956 | 10/20 | 0.80 |
| ▸ | LMNA | P02545 | 2/20 | 0.76 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.76 |
| ▸ | MAPT | P10636 | 2/20 | 0.76 |
| ▸ | MLNR | O43193 | 1/20 | 0.76 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.76 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.76 |
| ▸ | PPARG | P37231 | 1/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.76 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.76 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.75 |
| ▸ | DRD2 | P14416 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1943651 | 1.00 | NR3C1 (0.92) | NR3C1PGRCYP3A4USP2MEN1 | |
| SCHEMBL11878162 | 1.00 | NR3C1 (0.92) | NR3C1PGRCYP3A4USP2MEN1 | |
| SCHEMBL11858145 | 1.00 | NR3C1 (0.92) | NR3C1PGRCYP3A4USP2MEN1 | |
| SCHEMBL11878158 | 1.00 | NR3C1 (0.92) | NR3C1PGRCYP3A4USP2MEN1 | |
| SCHEMBL11852760 | 1.00 | NR3C1 (0.92) | NR3C1PGRCYP3A4USP2MEN1 | |
| SCHEMBL11852753 | 1.00 | NR3C1 (0.92) | NR3C1PGRCYP3A4USP2MEN1 | |
| Betamethasone Valerate SCHEMBL7564753 | 0.96 | NR3C1 (1.00) | NR3C1PGRCYP3A4USP2MEN1 | |
| Betamethasone Valerate SCHEMBL14339612 | 0.96 | NR3C1 (1.00) | NR3C1PGRCYP3A4USP2MEN1 | |
| Betamethasone Valerate SCHEMBL9768470 | 0.96 | NR3C1 (1.00) | NR3C1PGRCYP3A4USP2MEN1 | |
| Betamethasone Valerate SCHEMBL14339607 | 0.96 | NR3C1 (1.00) | NR3C1PGRCYP3A4USP2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210868-A1 | Methods of Treatment Using ICAM-Modulating Agents | AVM BIOTECHNOLOGY, LLC (US) | 2023-07-06 | — | — | US | claimed |
| CN-118302171-A | Lymphocyte populations and methods for producing the same | AVM生物技术有限责任公司 | 2024-07-05 | — | — | CN | disclosed |
| JP-2023108567-A | Method for producing steroid 17α,21-diesters | 同仁医薬化工株式会社 | 2023-08-04 | — | — | JP | disclosed |
| US-20230210868-A1 | Methods of Treatment Using ICAM-Modulating Agents | AVM BIOTECHNOLOGY, LLC (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230172950-A1 | Glucocorticoid Receptor (GR) Modulators for Treating a SARS-COV-2 Virus | AVM BIOTECHNOLOGY, LLC (US) | 2023-06-08 | — | — | US | disclosed |
| CN-116096421-A | Methods for treating remission-type multiple sclerosis | 渤健马萨诸塞州股份有限公司 | 2023-05-09 | — | — | CN | disclosed |
| US-20230096897-A1 | Lymphocyte Population and Methods for Producing Same | AVM BIOTECHNOLOGY, LLC (US) | 2023-03-30 | — | — | US | disclosed |
| WO-2023034377-A1 | LYMPHOCYTE POPULATION AND METHODS FOR PRODUCING SAME | AVM BIOTECHNOLOGY, LLC (US) | 2023-03-09 | — | — | WO | disclosed |
| EP-4142736-A1 | GLUCOCORTICOID RECEPTOR (GR) MODULATORS FOR TREATING A SARS-COV-2 VIRUS | AVM Biotechnology, LLC (US) | 2023-03-08 | — | — | EP | disclosed |
| CN-115666583-A | Glucocorticoid Receptor (GR) modulators for the treatment of SARS-COV-2 virus | AVM生物技术有限责任公司 | 2023-01-31 | — | — | CN | disclosed |
| US-7250546-B2 | Adhesive preparations | HISAMITSU PHARMACEUTICALS CO., INC. (JP) | 2007-07-31 | — | — | US | disclosed |
| US-20070083139-A1 | Adhesive preparations | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2007-04-12 | — | — | US | disclosed |
| EP-1238664-B1 | ADHESIVE PREPARATIONS | HISAMITSU PHARMACEUTICAL CO (JP) | 2007-02-14 | — | — | EP | disclosed |
| US-6835724-B2 | Topical antiinflammatory agents for treating inflammatory dermatoses | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-12-28 | — | — | US | disclosed |
| US-20030109819-A1 | Adhesive preparations | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2003-06-12 | — | — | US | disclosed |
| EP-1238664-A1 | ADHESIVE PREPARATIONS | HISAMITSU PHARMACEUTICAL CO. INC. (JP) | 2002-09-11 | — | — | EP | disclosed |
| US-20020103392-A1 | CORTICOID-17,21-DICARBOXYLIC ESTERS AND CORTICOSTEROID 17-CARBOXYLIC ESTER 21-CARBONIC ESTERS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICALS CONTAINING THESE COMPOUNDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-08-01 | — | — | US | disclosed |
| EP-0393658-B1 | Novel steroid derivatives | SS PHARMACEUTICAL CO (JP) | 1995-03-22 | — | — | EP | disclosed |
| EP-0393658-A2 | Novel steroid derivatives | SS PHARMACEUTICAL CO., LTD. (JP) | 1990-10-24 | — | — | EP | disclosed |
| US-4655971-A | USING AN ANHYDRIDE AND ACID CATALYST TO ESTERIFY HYDROXY'S IN THE 17- OR 17- AND 21-POSITION; ENHANCED ANTIINFLAMMATORY AGENTS | PLURICHEMIE ANSTALT (LI) | 1987-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103392-A1 | CORTICOID-17,21-DICARBOXYLIC ESTERS AND CORTICOSTEROID 17-CARBOXYLIC ESTER 21-CARBONIC ESTERS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICALS CONTAINING THESE COMPOUNDS | NR3C1, HSD3B1, HSD17B7 | NR3C1 1/4885PGR 707/4885CYP3A4 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.